A Randomized Controlled Observer Blind Trial to Compare the Immunogenicity and Acceptability of a MF59-adjuvanted Influenza Vaccine Compared to an Inactivated Influenza Vaccine as a Preferred Influenza Vaccine Priming Strategy for Naive Infants 6 to <24 Months of Age
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2019
Price : $35 *
At a glance
- Drugs Influenza virus vaccine (Primary) ; MF 59
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 11 Aug 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 11 Aug 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.